Key result
High-risk APOL1 genotypes are linked to ~58% higher risk of hospitalized HFpEF.
Cohort (n=11,137)
Answers are grounded in this paper and cite their sources.
Prospective cohort study shows high-risk APOL1 genotypes associate with preserved ejection fraction heart failure in postmenopausal African American women, highlighting kidney function pathways.
Importance: APOL1 genotypes are associated with kidney diseases in African American individuals and may influence cardiovascular disease and mortality risk, but findings have been inconsistent. Objective: To discern whether high-risk APOL1 genotypes are associated with cardiovascular disease and stroke in postmenopausal African American women, who are at high risk for these outcomes. Design, Setting, and Participants: The Women's Health Initiative is a prospective cohort that enrolled 161 838 postmenopausal women into clinical trials and an observational study between 1993 and 1998. This study includes 11 137 African American women participants who had a clinical event from enrollment to June 2014. Data analyses were completed from January 2017 to August 2017. Exposures: The variants of APOL1 were genotyped or imputed from whole-exome sequencing. Main Outcomes and Measures: Incident coronary heart disease, stroke and heart failure subtypes, and overall and cause-specific mortality were adjudicated from hospital records and death certificates. Estimated incidence rates were determined for each outcome and hazard ratios (HR) and 95% CIs for the associations of APOL1 groups with outcomes. Results: The mean (SD) age of participants was 61.7 (7.1) years. Carriers of high-risk APOL1 variants (n = 1370; 12.3%) had higher prevalence of hypertension, use of cholesterol-lowering medications, and reduced estimated glomerular filtration rate (eGFR). After a mean (SD) of 11.0 (3.6) years, carriers of high-risk APOL1 variants had a higher incidence rate of hospitalized heart failure with preserved ejection fraction (HFpEF) than low-risk carriers did but showed no differences for other outcomes. In adjusted models, there was a significant 58% increased hazard of hospitalized HFpEF (HR, 1.58 [95% CI, 1.03-2.41]) among carriers of high-risk APOL1 variants compared with carriers of low-risk APOL1 variants. The association with HFpEF was attenuated (HR = 1.50 [95% CI, 0.98-2.30]) and no longer significant when adjusting for baseline eGFR. Conclusions and Relevance: Status as a carrier of a high-risk APOL1 genotype was associated with HFpEF hospitalization among postmenopausal women, which is partly accounted for by baseline kidney function. These findings do not support an association of high-risk APOL1 genotypes with coronary heart disease, stroke, or mortality in postmenopausal African American women.
No takes yet. Share an insight, caveat, or question.
Franceschini et al. (2018) conducted a cohort in Cardiovascular disease, stroke, and heart failure subtypes (specifically hospitalized HFpEF) (n=11,137). High-risk APOL1 genotype variants vs. Low-risk APOL1 genotype variants was evaluated on Hospitalized heart failure with preserved ejection fraction (HFpEF) (HR 1.58, 95% CI 1.03-2.41). High-risk APOL1 genotypes were associated with an increased hazard of hospitalized HFpEF vs low-risk genotypes, attenuated after eGFR adjustment.
Synapse has enriched 10 related papers. Consider them for comparative context: